Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

Graduating School 【 display / non-display 】

Graduating School 【 display / non-display 】

• 　

  -

  1992.03

  Tohoku Pharmaceutical University   Faculty of Pharmaceutical Science   Graduated

Graduate School 【 display / non-display 】

Graduate School 【 display / non-display 】

• 　

  -

  1994.03

  Tohoku Pharmaceutical University  Graduate School, Division of Pharmaceutical Sciences  Master's Course  Completed

Campus Career 【 display / non-display 】

Campus Career 【 display / non-display 】

• 2021.12

  -

  Now

  Akita University   Graduate School of Medicine   Doctorial Course in Medicine   Bioregulatory Medicine   Department of Pharmacokinetics   Professor  

• 2013.04

  -

  2021.11

  Akita University   Hospital   Department of Pharmacy   Professor  

Research Achievements 【 display / non-display 】

Research Achievements 【 display / non-display 】

◆Original paper【 display / non-display 】

To the head of this page.▲

◆Original paper【 display / non-display 】

Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

Masatomo,Miura

Ther Drug Monit   29 ( 299 ) 304   2007.01

Research paper (journal)   Single author

Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

Masatomo,Miura

Eur J Clin Pharmacol   63 ( 279 ) 288   2007.01  [Refereed]

Research paper (journal)   Single author

Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography

Masatomo,Miura

J Pharm Biomed Anal   43 ( 741 ) 745   2007.01

Research paper (journal)   Single author

Pharmacokinetics of fexofenadine enantiomers in healthy subjects

Masatomo,Miura

Chirality   19 ( 223 ) 227   2007.01

Research paper (journal)   Single author

To the head of this page.▲

◆Other【 display / non-display 】

To the head of this page.▲

◆Other【 display / non-display 】

Simultaneous Determination of Serum Concentrations of Phenytoin and Carbamazepine with LM1010 High-Performance Liquid Chromatography and Comparison with CLIA

Akamine Yumiko, Matsushita Miyuki, Morikawa Satoru, Miura Masatomo

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) ( Japanese Society of Pharmaceutical Health Care and Sciences )  50 ( 9 ) 465 - 472   2024.09

DOI CiNii Research

Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia

Kobayashi Takahiro, Honami Sato, Miura Masatomo, Fukushi Yayoi, Kuroki Wataru, Ito Fumiko, Teshima Kazuaki, Watanabe Atsushi, Fujishima Naohito, Kobayashi Isuzu, Kameoka Yoshihiro, Takahashi Naoto

Cancer Chemotherapy and Pharmacology ( Springer Nature )    2024

CiNii Research

Evaluation of Plasma Concentrations of Mycophenolic Acid in Renal Transplant Patients Using LM1010 High-performance Liquid Chromatography

Akamine Yumiko, Matsushita Miyuki, Morikawa Satoru, Miura Masatomo

YAKUGAKU ZASSHI ( The Pharmaceutical Society of Japan )  143 ( 4 ) 377 - 383   2023

DOI PubMed CiNii Research

Determination of Plasma Concentrations of Imatinib by a Novel Automated Analyzer Based on High-Performance Liquid Chromatography

Fukushi Yayoi, Akamine Yumiko, Matsushita Miyuki, Morikawa Satoru, Miura Masatomo

YAKUGAKU ZASSHI ( The Pharmaceutical Society of Japan )  143 ( 11 ) 963 - 969   2023

DOI CiNii Research

An Investigational Study to Establish the Basic Construction of Precision Medicine from a Pharmaceutical Perspective

Tsuji Daiki, Saito Yoshiro, Mushiroda Taisei, Miura Masatomo, Hira Daiki, Terada Tomohiro

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) ( Japanese Society of Pharmaceutical Health Care and Sciences )  46 ( 2 ) 66 - 76   2020

<p>Given that the cancer gene panel test was approved in June 2019, precision medicine based on the information about somatic mutation is expected to be widely available. Similarly, pharmacogenomics (PGx) associated with germline genes, such as drug-metabolizing enzymes, could also be effective tools. However, its clinical implementation has been delayed.</p><p>To address this issue, we conducted a survey regarding pharmacists' involvement in "cancer genomic medicine (CGM)" and actual use of PGx and therapeutic drug monitoring (TDM). The response rate of the survey was 96.8% (121/125).</p><p>According to this survey, genetic polymorphism analysis for irinotecan (UGT1A1), which is approved for genetic testing, was most commonly used. Among the tests not covered by insurance, tacrolimus (CYP3A5) and voriconazole (CYP2C19) were commonly used. Only a few facilities conducted PGx tests. Unlike PGx, many drugs are covered by insurance for TDM, which was commonly used. Vancomycin was most commonly used, followed by teicoplanin and cyclosporine. Regarding CGM, it was found that the pharmacists were most commonly involved in dose adjustment support, followed by support for selection of anti-cancer agents. Pharmacists' participation in the expert panel was 21.3%.</p><p>This survey revealed that PGx testing is less common compared with TDM. PGx of drug-metabolizing enzymes could potentially influence adverse reactions and efficacy. It might be possible to provide individualized pharmacotherapy if PGx testing could be performed at the same time as gene panel tests. Insurance-covered PGx testing may increase in the future if more high-quality clinical trials are conducted and its usefulness is validated.</p>

DOI CiNii Research

display all >>

Grant-in-Aid for Scientific Research 【 display / non-display 】

Grant-in-Aid for Scientific Research 【 display / non-display 】

• Grant-in-Aid for Scientific Research(C)

  Project Year： 2020.04  -  2022.03